Beneficial effects of an intradialytic cycling training program in patients with end-stage kidney disease

Applied Physiology, Nutrition and Metabolism - Tập 40 Số 6 - Trang 550-556 - 2015
Carole Groussard1, Myriam Rouchon-Isnard2, Céline Coutard2, Fanny Romain2, Ludivine Malardé1, Sophie Lemoine-Morel1, Brice Martin1, Bruno Pereira3, Nathalie Boisseau4
1Laboratory “Movement, Sport and Health Sciences” (M2S), Rennes 2 University–ENS Cachan, Avenue Robert Schuman, Campus de Ker Lann, F-35170 Bruz, France.
2AURA Auvergne, 8 rue du Colombier, F-63400 Chamalières, France.
3University Hospital Center (CHU) of Clermont-Ferrand, Biostatistics Unit, DRCI, F-63000 Clermont-Ferrand, France.
4Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Université Blaise Pascal, Campus Universitaire des Cézeaux, Bât. Biologie B, 5 impasse Amélie Murat, TSA 60026, CS 60026, 63178 Aubière Cedex, France.

Tóm tắt

In chronic kidney disease (CKD), oxidative stress (OS) plays a central role in the development of cardiovascular diseases. This pilot program aimed to determine whether an intradialytic aerobic cycling training protocol, by increasing physical fitness, could reduce OS and improve other CKD-related disorders such as altered body composition and lipid profile. Eighteen hemodialysis patients were randomly assigned to either an intradialytic training (cycling: 30 min, 55%–60% peak power, 3 days/week) group (EX; n = 8) or a control group (CON; n = 10) for 3 months. Body composition (from dual-energy X-ray absorptiometry), physical fitness (peak oxygen uptake and the 6-minute walk test (6MWT)), lipid profile (triglycerides (TG), total cholesterol, high-density lipoprotein, and low-density lipoprotein (LDL)), and pro/antioxidant status (15-F-isoprostanes (F2-IsoP) and oxidized LDL in plasma; superoxide dismutase, glutathione peroxidase, and reduced/oxidized glutathione in erythrocytes) were determined at baseline and 3 months later. The intradialytic training protocol did not modify body composition but had significant effects on physical fitness, lipid profile, and pro/antioxidant status. Indeed, at 3 months: (i) performance on the 6MWT was increased in EX (+23.4%, p < 0.001) but did not change in CON, (ii) plasma TG were reduced in EX (–23%, p < 0.03) but were not modified in CON, and (iii) plasma F2-IsoP concentrations were lower in EX than in CON (–35.7%, p = 0.02). In conclusion, our results show that 30 min of intradialytic training, 3 times per week for 3 months, are enough to exert beneficial effects on the most sensitive and reliable marker of lipid peroxidation (IsoP) while improving CKD-associated disorders (lipid profile and physical fitness). Intradialytic aerobic cycling training represents a useful and easy strategy to reduce CKD-associated disorders. These results need to be confirmed with a larger randomized study.

Từ khóa


Tài liệu tham khảo

10.1164/ajrccm.166.1.at1102

10.1016/S0140-6736(00)02456-9

10.1016/j.maturitas.2012.05.015

10.1053/j.ajkd.2005.01.030

10.1053/j.jrn.2009.10.007

10.1016/S0735-1097(01)01321-3

10.1097/00002060-199501000-00009

Friedewald W.T., 1972, Clin. Chem., 18, 499, 10.1093/clinchem/18.6.499

Goldberg A.P., 1983, Kidney Int., 16, S303

10.1016/j.freeradbiomed.2007.02.001

10.1016/0033-0620(83)90027-0

Hawley J.A., 2009, Rev., 67, 172

10.1053/j.ajkd.2014.03.020

10.1111/j.0894-0959.2004.17605.x

10.1016/0891-5849(90)90131-2

10.1161/01.CIR.97.11.1029

10.1080/165019702317242695

10.2165/11536880-000000000-00000

Kouidi E., 1998, Nephrol. Dial. Transplant, 13, 685, 10.1093/ndt/13.3.685

Martin C.J., 2005, Nephrol. Nurs. J., 32, 683

10.1007/s004210000342

Morrow J.D., 1992, Prostaglandins, 44, 155, 10.1016/0090-6980(92)90077-7

10.1016/S0272-6386(00)70241-1

O’Hare A.M., 2003, Am. J. Kidney Dis., 41, 447, 10.1053/ajkd.2003.50055

10.1007/BF00640658

10.1111/j.1492-7535.2005.01136.x

10.1016/S0272-6386(00)70202-2

10.1016/j.apmr.2005.12.044

10.1097/00004356-200306000-00013

10.1016/S0891-5849(99)00264-6

10.1016/j.freeradbiomed.2011.09.022

10.1016/S0140-6736(00)04728-0

10.1111/j.1525-139X.2010.00766.x

10.1111/j.1523-1755.2004.00411.x

10.1111/j.1440-1797.2011.01471.x

Storer T.W., 2005, Nephrol. Dial. Transplant, 20, 1429, 10.1093/ndt/gfh784

10.1681/ASN.2005101085

10.1006/abbi.1999.1494

Vogiatzi G., 2009, Hellenic J. Cardiol., 50, 402

Wilund K.R., 2010, Nephrol. Dial. Transplant, 25, 2695, 10.1093/ndt/gfq106

10.1081/COPD-200050527

10.1038/ijo.2009.49

Zoccali C., 2002, J. Am. Soc. Nephrol., 13, 134, 10.1097/01.ASN.0000032548.18973.0F